Analysis of Liver Transplantation Outcome in Patients With MELD Score ≥30

Since July 2006, the liver graft allocation has been changed from the waiting time to the Model for End-stage Liver Disease (MELD), prioritizing the sickest patients, who have a higher risk of dying on the waiting list, and sometimes in such poor clinical condition that it compromises transplantatio...

Full description

Saved in:
Bibliographic Details
Published inTransplantation proceedings Vol. 40; no. 3; pp. 797 - 799
Main Authors Ferraz-Neto, B.H., Zurstrassen, M.P.V.C., Hidalgo, R., Meira-Filho, S.P., Rezende, M.B., Paes, A.T., Afonso, R.C.
Format Journal Article Conference Proceeding
LanguageEnglish
Published New York, NY Elsevier Inc 01.04.2008
Elsevier Science
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Since July 2006, the liver graft allocation has been changed from the waiting time to the Model for End-stage Liver Disease (MELD), prioritizing the sickest patients, who have a higher risk of dying on the waiting list, and sometimes in such poor clinical condition that it compromises transplantation outcomes. The aim of this study was to analyze the impact of a MELD score ≥ 30 on 30-day survival after liver transplantation (OLT). We prospectively collected the data on 178 liver transplants on 163 patients performed from March 2003 to August 2007. The subjects were divided in two groups according to their MELD scores: group 1, MELD ≥ 30 ( n = 15) and group 2, MELD < 30 ( n = 96). The groups were compared with regard to hospital and intensive care unit (ICU) length of stay, intraoperative blood products transfusion, early survival (30 days), and need for retransplantation. We excluded, patients with prioritization criteria, those receiving extra points for any special situation, and six other patients without significant data for MELD calculation (of whom only one has died after transplantation). Patients under a “special situation” were those with hepatocelular carcinoma, hepatopulmonary syndrome, and metabolic diseases, who initially received a MELD/PELD score 20, and 24, and 29. The mean MELD score at group I was 34 (range, 30 to 42), and for group II it was 16 (range, 6 to 29). Group I displayed a mean hospital length of stay of 24 days (4 to 155), with 12.60 days (ranges, 1 to 103) in the ICU versus 15.55 (range, 1 to 48) and 5.13 (range, 1 to 45) days, respectively, for group II. The need for blood component transfusions were greater in group I; 25.28% of patients in group II did not receive any transfusion during the entire inpatient period. There were nine retransplants in group II, and none in group I. The 30-day survivals were 93.3% for group I and 84.37% for group II. Besides the increased complexity of these sickest patients, there was no negative impact on early survival rates.
AbstractList Since July 2006, the liver graft allocation has been changed from the waiting time to the Model for End-stage Liver Disease (MELD), prioritizing the sickest patients, who have a higher risk of dying on the waiting list, and sometimes in such poor clinical condition that it compromises transplantation outcomes. The aim of this study was to analyze the impact of a MELD score > or = 30 on 30-day survival after liver transplantation (OLT). We prospectively collected the data on 178 liver transplants on 163 patients performed from March 2003 to August 2007. The subjects were divided in two groups according to their MELD scores: group 1, MELD > or = 30 (n = 15) and group 2, MELD < 30 (n = 96). The groups were compared with regard to hospital and intensive care unit (ICU) length of stay, intraoperative blood products transfusion, early survival (30 days), and need for retransplantation. We excluded, patients with prioritization criteria, those receiving extra points for any special situation, and six other patients without significant data for MELD calculation (of whom only one has died after transplantation). Patients under a "special situation" were those with hepatocelular carcinoma, hepatopulmonary syndrome, and metabolic diseases, who initially received a MELD/PELD score 20, and 24, and 29. The mean MELD score at group I was 34 (range, 30 to 42), and for group II it was 16 (range, 6 to 29). Group I displayed a mean hospital length of stay of 24 days (4 to 155), with 12.60 days (ranges, 1 to 103) in the ICU versus 15.55 (range, 1 to 48) and 5.13 (range, 1 to 45) days, respectively, for group II. The need for blood component transfusions were greater in group I; 25.28% of patients in group II did not receive any transfusion during the entire inpatient period. There were nine retransplants in group II, and none in group I. The 30-day survivals were 93.3% for group I and 84.37% for group II. Besides the increased complexity of these sickest patients, there was no negative impact on early survival rates.Since July 2006, the liver graft allocation has been changed from the waiting time to the Model for End-stage Liver Disease (MELD), prioritizing the sickest patients, who have a higher risk of dying on the waiting list, and sometimes in such poor clinical condition that it compromises transplantation outcomes. The aim of this study was to analyze the impact of a MELD score > or = 30 on 30-day survival after liver transplantation (OLT). We prospectively collected the data on 178 liver transplants on 163 patients performed from March 2003 to August 2007. The subjects were divided in two groups according to their MELD scores: group 1, MELD > or = 30 (n = 15) and group 2, MELD < 30 (n = 96). The groups were compared with regard to hospital and intensive care unit (ICU) length of stay, intraoperative blood products transfusion, early survival (30 days), and need for retransplantation. We excluded, patients with prioritization criteria, those receiving extra points for any special situation, and six other patients without significant data for MELD calculation (of whom only one has died after transplantation). Patients under a "special situation" were those with hepatocelular carcinoma, hepatopulmonary syndrome, and metabolic diseases, who initially received a MELD/PELD score 20, and 24, and 29. The mean MELD score at group I was 34 (range, 30 to 42), and for group II it was 16 (range, 6 to 29). Group I displayed a mean hospital length of stay of 24 days (4 to 155), with 12.60 days (ranges, 1 to 103) in the ICU versus 15.55 (range, 1 to 48) and 5.13 (range, 1 to 45) days, respectively, for group II. The need for blood component transfusions were greater in group I; 25.28% of patients in group II did not receive any transfusion during the entire inpatient period. There were nine retransplants in group II, and none in group I. The 30-day survivals were 93.3% for group I and 84.37% for group II. Besides the increased complexity of these sickest patients, there was no negative impact on early survival rates.
Since July 2006, the liver graft allocation has been changed from the waiting time to the Model for End-stage Liver Disease (MELD), prioritizing the sickest patients, who have a higher risk of dying on the waiting list, and sometimes in such poor clinical condition that it compromises transplantation outcomes. The aim of this study was to analyze the impact of a MELD score ≥ 30 on 30-day survival after liver transplantation (OLT). We prospectively collected the data on 178 liver transplants on 163 patients performed from March 2003 to August 2007. The subjects were divided in two groups according to their MELD scores: group 1, MELD ≥ 30 ( n = 15) and group 2, MELD < 30 ( n = 96). The groups were compared with regard to hospital and intensive care unit (ICU) length of stay, intraoperative blood products transfusion, early survival (30 days), and need for retransplantation. We excluded, patients with prioritization criteria, those receiving extra points for any special situation, and six other patients without significant data for MELD calculation (of whom only one has died after transplantation). Patients under a “special situation” were those with hepatocelular carcinoma, hepatopulmonary syndrome, and metabolic diseases, who initially received a MELD/PELD score 20, and 24, and 29. The mean MELD score at group I was 34 (range, 30 to 42), and for group II it was 16 (range, 6 to 29). Group I displayed a mean hospital length of stay of 24 days (4 to 155), with 12.60 days (ranges, 1 to 103) in the ICU versus 15.55 (range, 1 to 48) and 5.13 (range, 1 to 45) days, respectively, for group II. The need for blood component transfusions were greater in group I; 25.28% of patients in group II did not receive any transfusion during the entire inpatient period. There were nine retransplants in group II, and none in group I. The 30-day survivals were 93.3% for group I and 84.37% for group II. Besides the increased complexity of these sickest patients, there was no negative impact on early survival rates.
Abstract Since July 2006, the liver graft allocation has been changed from the waiting time to the Model for End-stage Liver Disease (MELD), prioritizing the sickest patients, who have a higher risk of dying on the waiting list, and sometimes in such poor clinical condition that it compromises transplantation outcomes. The aim of this study was to analyze the impact of a MELD score ≥ 30 on 30-day survival after liver transplantation (OLT). We prospectively collected the data on 178 liver transplants on 163 patients performed from March 2003 to August 2007. The subjects were divided in two groups according to their MELD scores: group 1, MELD ≥ 30 ( n = 15) and group 2, MELD < 30 ( n = 96). The groups were compared with regard to hospital and intensive care unit (ICU) length of stay, intraoperative blood products transfusion, early survival (30 days), and need for retransplantation. We excluded, patients with prioritization criteria, those receiving extra points for any special situation, and six other patients without significant data for MELD calculation (of whom only one has died after transplantation). Patients under a “special situation” were those with hepatocelular carcinoma, hepatopulmonary syndrome, and metabolic diseases, who initially received a MELD/PELD score 20, and 24, and 29. The mean MELD score at group I was 34 (range, 30 to 42), and for group II it was 16 (range, 6 to 29). Group I displayed a mean hospital length of stay of 24 days (4 to 155), with 12.60 days (ranges, 1 to 103) in the ICU versus 15.55 (range, 1 to 48) and 5.13 (range, 1 to 45) days, respectively, for group II. The need for blood component transfusions were greater in group I; 25.28% of patients in group II did not receive any transfusion during the entire inpatient period. There were nine retransplants in group II, and none in group I. The 30-day survivals were 93.3% for group I and 84.37% for group II. Besides the increased complexity of these sickest patients, there was no negative impact on early survival rates.
Since July 2006, the liver graft allocation has been changed from the waiting time to the Model for End-stage Liver Disease (MELD), prioritizing the sickest patients, who have a higher risk of dying on the waiting list, and sometimes in such poor clinical condition that it compromises transplantation outcomes. The aim of this study was to analyze the impact of a MELD score > or = 30 on 30-day survival after liver transplantation (OLT). We prospectively collected the data on 178 liver transplants on 163 patients performed from March 2003 to August 2007. The subjects were divided in two groups according to their MELD scores: group 1, MELD > or = 30 (n = 15) and group 2, MELD < 30 (n = 96). The groups were compared with regard to hospital and intensive care unit (ICU) length of stay, intraoperative blood products transfusion, early survival (30 days), and need for retransplantation. We excluded, patients with prioritization criteria, those receiving extra points for any special situation, and six other patients without significant data for MELD calculation (of whom only one has died after transplantation). Patients under a "special situation" were those with hepatocelular carcinoma, hepatopulmonary syndrome, and metabolic diseases, who initially received a MELD/PELD score 20, and 24, and 29. The mean MELD score at group I was 34 (range, 30 to 42), and for group II it was 16 (range, 6 to 29). Group I displayed a mean hospital length of stay of 24 days (4 to 155), with 12.60 days (ranges, 1 to 103) in the ICU versus 15.55 (range, 1 to 48) and 5.13 (range, 1 to 45) days, respectively, for group II. The need for blood component transfusions were greater in group I; 25.28% of patients in group II did not receive any transfusion during the entire inpatient period. There were nine retransplants in group II, and none in group I. The 30-day survivals were 93.3% for group I and 84.37% for group II. Besides the increased complexity of these sickest patients, there was no negative impact on early survival rates.
Author Ferraz-Neto, B.H.
Rezende, M.B.
Paes, A.T.
Hidalgo, R.
Meira-Filho, S.P.
Afonso, R.C.
Zurstrassen, M.P.V.C.
Author_xml – sequence: 1
  givenname: B.H.
  surname: Ferraz-Neto
  fullname: Ferraz-Neto, B.H.
  email: ben-hur@einstein.br
– sequence: 2
  givenname: M.P.V.C.
  surname: Zurstrassen
  fullname: Zurstrassen, M.P.V.C.
– sequence: 3
  givenname: R.
  surname: Hidalgo
  fullname: Hidalgo, R.
– sequence: 4
  givenname: S.P.
  surname: Meira-Filho
  fullname: Meira-Filho, S.P.
– sequence: 5
  givenname: M.B.
  surname: Rezende
  fullname: Rezende, M.B.
– sequence: 6
  givenname: A.T.
  surname: Paes
  fullname: Paes, A.T.
– sequence: 7
  givenname: R.C.
  surname: Afonso
  fullname: Afonso, R.C.
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20384646$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/18455020$$D View this record in MEDLINE/PubMed
BookMark eNqNkttuEzEQhi3UiqYtr4AsJLjbrU_rrLlAlLYcRFCRWsSl5XhnhcNmXezdSnkEHoQX40mYkHBQpUq5ssbzz6eZ-eeQ7PWxB0KecFZyxvXJohyS6_NNih6gKQVjdclkiakHZMLrqSyEFnKPTBhTvOBSVQfkMOcFw1go-ZAc8FpVFRNsQt6f9q5b5ZBpbOks3EKi17_hnesHN4TY08tx8HEJNPT0I_5AP2T6OQxf6IeL2Tm98jEB_fn9h2THZL91XYZH2_eIfHp9cX32tphdvnl3djorfCXEUCjOnZHGNE0lal3V2L7RrWm55kLxppnrhs0d80ZIo_m0ao2vdeta5WqmKm_kEXm24eIGvo2QB7sM2UOHLUMcs9WGT03FJQofb4XjfAmNvUlh6dLK_hkfBU-3Ape961qc3If8V4eKWmmlUfd8o_Mp5pyg_Ydidu2JXdj_PbFrTyyTFlNY_PJOsQ-b1WJJ6HZDnG8QgGu9DZBs9miEhyYk8INtYtgN8-IOxnehDzj5V1hBXsQx4TVky20Wltmr9f2sz4ehR4IbhYBX9wN27eIX8brbmw
CODEN TRPPA8
CitedBy_id crossref_primary_10_1007_s00595_013_0513_9
crossref_primary_10_1007_s00101_010_1822_7
crossref_primary_10_1097_MD_0000000000002320
crossref_primary_10_4097_kja_19108
crossref_primary_10_1111_j_1432_2277_2009_00929_x
crossref_primary_10_1111_myc_12041
crossref_primary_10_1111_j_1432_2277_2009_00915_x
crossref_primary_10_1007_s11377_009_0332_0
crossref_primary_10_1155_2012_264015
crossref_primary_10_1111_j_1432_2277_2010_01161_x
crossref_primary_10_1590_S1807_59322011000100011
crossref_primary_10_1186_cc9068
crossref_primary_10_1016_j_transproceed_2023_03_011
crossref_primary_10_15591_mtp_2015_057
crossref_primary_10_1111_tri_12058
crossref_primary_10_1016_j_transproceed_2009_12_059
crossref_primary_10_1177_1944451612439315
crossref_primary_10_1007_s12149_009_0250_8
crossref_primary_10_1016_j_transci_2015_07_008
crossref_primary_10_4254_wjh_v9_i36_1346
crossref_primary_10_1590_S1679_45082012000100012
crossref_primary_10_1016_j_transproceed_2016_08_003
crossref_primary_10_6002_ect_2019_0077
crossref_primary_10_1177_14777509211016286
crossref_primary_10_1186_1471_2253_14_103
crossref_primary_10_1371_journal_pone_0152324
crossref_primary_10_1016_j_transproceed_2014_10_032
crossref_primary_10_4236_ojepi_2023_134019
crossref_primary_10_1111_j_1399_0012_2010_01364_x
Cites_doi 10.1016/j.transproceed.2005.05.007
10.1016/j.transproceed.2006.02.107
10.1111/j.1478-3231.2004.00888.x
10.1111/j.1600-6143.2006.01490.x
10.1111/j.1600-6143.2006.01702.x
10.1097/01.tp.0000238705.29588.fc
10.1111/j.1365-2036.2005.02321.x
10.1016/j.transproceed.2006.03.008
10.1016/j.transproceed.2006.10.034
10.1111/j.1478-3231.2007.01494.x
10.1111/j.1600-6143.2006.01354.x
10.1053/he.2000.5852
10.1111/j.1600-6143.2006.01242.x
10.1007/s10620-006-8011-1
ContentType Journal Article
Conference Proceeding
Copyright 2008 Elsevier Inc.
Elsevier Inc.
2008 INIST-CNRS
Copyright_xml – notice: 2008 Elsevier Inc.
– notice: Elsevier Inc.
– notice: 2008 INIST-CNRS
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1016/j.transproceed.2008.03.016
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic


MEDLINE

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Anatomy & Physiology
Biology
Pharmacy, Therapeutics, & Pharmacology
EISSN 1873-2623
EndPage 799
ExternalDocumentID 18455020
20384646
10_1016_j_transproceed_2008_03_016
S0041134508002194
1_s2_0_S0041134508002194
Genre Journal Article
GroupedDBID ---
--K
--M
.1-
.55
.FO
.GJ
.~1
0R~
123
1B1
1P~
1~.
1~5
29Q
3O-
4.4
457
4G.
53G
5RE
5VS
7-5
71M
8P~
AABNK
AAEDT
AAEDW
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQXK
AATTM
AAXKI
AAXUO
AAYWO
ABBQC
ABFRF
ABJNI
ABLJU
ABMAC
ABMZM
ABOCM
ABWVN
ABXDB
ACDAQ
ACGFO
ACIEU
ACIUM
ACRLP
ACRPL
ACVFH
ADBBV
ADCNI
ADEZE
ADMUD
ADNMO
AEBSH
AEFWE
AEIPS
AEKER
AENEX
AEUPX
AEVXI
AFJKZ
AFPUW
AFRHN
AFTJW
AFXIZ
AGCQF
AGHFR
AGQPQ
AGUBO
AGYEJ
AIEXJ
AIGII
AIIUN
AIKHN
AITUG
AJRQY
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANKPU
ANZVX
APXCP
ASPBG
AVWKF
AXJTR
AZFZN
BKOJK
BLXMC
BNPGV
CS3
DU5
EBS
EFJIC
EFKBS
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
G-Q
GBLVA
HVGLF
HZ~
IHE
J1W
J5H
K-O
KOM
L7B
M41
MO0
N9A
O-L
O9-
OAUVE
OK-
OW-
OZT
P-8
P-9
P2P
PC.
Q38
R2-
ROL
RPZ
SCC
SDF
SDG
SDP
SEL
SES
SEW
SPCBC
SSH
SSZ
T5K
UDS
WH7
X7M
XPP
Y6R
Z5R
ZGI
ZXP
~G-
AACTN
AFCTW
AFKWA
AJOXV
AMFUW
RIG
AAIAV
ABLVK
ABYKQ
AHPSJ
AJBFU
EFLBG
LCYCR
ZA5
AAYXX
AGRNS
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-c522t-411a9399dd52865800896f9f161241ddb6d0ba0c92396175f9c86faf4a8045c93
IEDL.DBID AIKHN
ISSN 0041-1345
IngestDate Fri Jul 11 00:58:25 EDT 2025
Thu Apr 03 07:06:24 EDT 2025
Mon Jul 21 09:17:14 EDT 2025
Thu Apr 24 22:51:09 EDT 2025
Tue Jul 01 04:19:37 EDT 2025
Fri Feb 23 02:33:26 EST 2024
Sun Feb 23 10:19:46 EST 2025
Tue Aug 26 17:18:14 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords Human
Prognosis
Digestive system
Liver
Hepatic disease
Patient
Homotransplantation
Medicine
Liver failure
Score
Treatment
Surgery
Analysis
Digestive diseases
Evolution
Graft
Models
Liver transplantation
Language English
License https://www.elsevier.com/tdm/userlicense/1.0
CC BY 4.0
LinkModel DirectLink
MeetingName Joint Congresses of the 10TH Transplantation Society of Brazil, 19TH Latin American and Caribbean Transplantation Society, and 6TH Luso-Brazilian Transplantation Society
MergedId FETCHMERGED-LOGICAL-c522t-411a9399dd52865800896f9f161241ddb6d0ba0c92396175f9c86faf4a8045c93
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 18455020
PQID 69179513
PQPubID 23479
PageCount 3
ParticipantIDs proquest_miscellaneous_69179513
pubmed_primary_18455020
pascalfrancis_primary_20384646
crossref_primary_10_1016_j_transproceed_2008_03_016
crossref_citationtrail_10_1016_j_transproceed_2008_03_016
elsevier_sciencedirect_doi_10_1016_j_transproceed_2008_03_016
elsevier_clinicalkeyesjournals_1_s2_0_S0041134508002194
elsevier_clinicalkey_doi_10_1016_j_transproceed_2008_03_016
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2008-04-01
PublicationDateYYYYMMDD 2008-04-01
PublicationDate_xml – month: 04
  year: 2008
  text: 2008-04-01
  day: 01
PublicationDecade 2000
PublicationPlace New York, NY
PublicationPlace_xml – name: New York, NY
– name: United States
PublicationTitle Transplantation proceedings
PublicationTitleAlternate Transplant Proc
PublicationYear 2008
Publisher Elsevier Inc
Elsevier Science
Publisher_xml – name: Elsevier Inc
– name: Elsevier Science
References Ravaioli, Grazi, Ballardini (bib5) 2006; 6
Xu, Ling, Wu (bib8) 2007; 6
Malinchoc, Kamath, Gordon (bib2) 2000; 31
Feng, Goodrich, Bragg-Greham (bib13) 2006; 6
Sachdev, Hernandez, Sharma (bib1) 2006; 6
Avolio, Agnes, Gasbarrini (bib10) 2006; 38
Avolio, Agnes, Gasbarrini (bib9) 2006; 38
Wang, Saab (bib14) 2004; 24
Kanwal, Dulai, Spiegel (bib3) 2005; 21
Washburn, Pollock, Nichols (bib4) 2006; 6
Johnson, Alexopoulos, Curry (bib12) 2007; 7
Adler, De Gendt, Vereerstraeten (bib6) 2005; 37
Ravaioli, Grazi, Ercolani (bib7) 2006; 7
Xia, Fond, Du (bib11) 2006; 38
Wang (10.1016/j.transproceed.2008.03.016_bib14) 2004; 24
Avolio (10.1016/j.transproceed.2008.03.016_bib9) 2006; 38
Kanwal (10.1016/j.transproceed.2008.03.016_bib3) 2005; 21
Sachdev (10.1016/j.transproceed.2008.03.016_bib1) 2006; 6
Ravaioli (10.1016/j.transproceed.2008.03.016_bib7) 2006; 7
Xu (10.1016/j.transproceed.2008.03.016_bib8) 2007; 6
Xia (10.1016/j.transproceed.2008.03.016_bib11) 2006; 38
Johnson (10.1016/j.transproceed.2008.03.016_bib12) 2007; 7
Feng (10.1016/j.transproceed.2008.03.016_bib13) 2006; 6
Avolio (10.1016/j.transproceed.2008.03.016_bib10) 2006; 38
Adler (10.1016/j.transproceed.2008.03.016_bib6) 2005; 37
Malinchoc (10.1016/j.transproceed.2008.03.016_bib2) 2000; 31
Washburn (10.1016/j.transproceed.2008.03.016_bib4) 2006; 6
Ravaioli (10.1016/j.transproceed.2008.03.016_bib5) 2006; 6
References_xml – volume: 6
  start-page: 1572
  year: 2006
  ident: bib5
  article-title: Liver transplantation with the MELD system: A prospective study from a single European center
  publication-title: Am J Transplant
– volume: 37
  start-page: 2863
  year: 2005
  ident: bib6
  article-title: Value of the MELD score for the assessment of pre- and post-liver transplantation survival
  publication-title: Transplant Proc
– volume: 38
  start-page: 1398
  year: 2006
  ident: bib11
  article-title: Ascites, but not hyponaremia, is associated with high intraoperative transfusion and vasopressor requirements during liver transplantation
  publication-title: Transplant Proc
– volume: 6
  start-page: 783
  year: 2006
  ident: bib13
  article-title: Characteristics associated with liver graft failure: The concept of a donor risk index
  publication-title: Am J Transplant
– volume: 24
  start-page: 1
  year: 2004
  ident: bib14
  article-title: Liver transplantation in the era of model for end-stage liver disease
  publication-title: Liver Int
– volume: 38
  start-page: 3567
  year: 2006
  ident: bib9
  article-title: Allocation of nonstandard livers to transplant candidates with high MELD scores: should this practice be continued?
  publication-title: Transplant Proc
– volume: 6
  start-page: 1070
  year: 2006
  ident: bib1
  article-title: Liver transplantation in the MELD era: a single center experience
  publication-title: Dig Dis Sci
– volume: 7
  start-page: 1003
  year: 2007
  ident: bib12
  article-title: Primary nonfunction (PNF) in the MELD era: an SRTR database analysis
  publication-title: Am J Transplant
– volume: 21
  start-page: 169
  year: 2005
  ident: bib3
  article-title: A comparison of liver transplantation outcomes in the pre- vs. post-MELD eras
  publication-title: Aliment Pharmacol Ther
– volume: 6
  start-page: 816
  year: 2007
  ident: bib8
  article-title: A novel prognostic model based on serum levels of total bilirubin and creatinina early after liver transplantation
  publication-title: Liver Int
– volume: 31
  start-page: 864
  year: 2000
  ident: bib2
  article-title: A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts
  publication-title: Hepatology
– volume: 6
  start-page: 2449
  year: 2006
  ident: bib4
  article-title: Impact of recipient MELD score o resource utilization
  publication-title: Am J Transplant
– volume: 38
  start-page: 1059
  year: 2006
  ident: bib10
  article-title: Prognostic value of MELD score and donor quality in liver transplantation: Implications for the donor recipient match
  publication-title: Transplant Proc
– volume: 7
  start-page: 987
  year: 2006
  ident: bib7
  article-title: The future challenge in the MELD era: how to match extended-use donors and sick recipients
  publication-title: Transplantation
– volume: 37
  start-page: 2863
  year: 2005
  ident: 10.1016/j.transproceed.2008.03.016_bib6
  article-title: Value of the MELD score for the assessment of pre- and post-liver transplantation survival
  publication-title: Transplant Proc
  doi: 10.1016/j.transproceed.2005.05.007
– volume: 38
  start-page: 1398
  year: 2006
  ident: 10.1016/j.transproceed.2008.03.016_bib11
  article-title: Ascites, but not hyponaremia, is associated with high intraoperative transfusion and vasopressor requirements during liver transplantation
  publication-title: Transplant Proc
  doi: 10.1016/j.transproceed.2006.02.107
– volume: 24
  start-page: 1
  year: 2004
  ident: 10.1016/j.transproceed.2008.03.016_bib14
  article-title: Liver transplantation in the era of model for end-stage liver disease
  publication-title: Liver Int
  doi: 10.1111/j.1478-3231.2004.00888.x
– volume: 6
  start-page: 2449
  year: 2006
  ident: 10.1016/j.transproceed.2008.03.016_bib4
  article-title: Impact of recipient MELD score o resource utilization
  publication-title: Am J Transplant
  doi: 10.1111/j.1600-6143.2006.01490.x
– volume: 7
  start-page: 1003
  year: 2007
  ident: 10.1016/j.transproceed.2008.03.016_bib12
  article-title: Primary nonfunction (PNF) in the MELD era: an SRTR database analysis
  publication-title: Am J Transplant
  doi: 10.1111/j.1600-6143.2006.01702.x
– volume: 7
  start-page: 987
  year: 2006
  ident: 10.1016/j.transproceed.2008.03.016_bib7
  article-title: The future challenge in the MELD era: how to match extended-use donors and sick recipients
  publication-title: Transplantation
  doi: 10.1097/01.tp.0000238705.29588.fc
– volume: 21
  start-page: 169
  year: 2005
  ident: 10.1016/j.transproceed.2008.03.016_bib3
  article-title: A comparison of liver transplantation outcomes in the pre- vs. post-MELD eras
  publication-title: Aliment Pharmacol Ther
  doi: 10.1111/j.1365-2036.2005.02321.x
– volume: 38
  start-page: 1059
  year: 2006
  ident: 10.1016/j.transproceed.2008.03.016_bib10
  article-title: Prognostic value of MELD score and donor quality in liver transplantation: Implications for the donor recipient match
  publication-title: Transplant Proc
  doi: 10.1016/j.transproceed.2006.03.008
– volume: 38
  start-page: 3567
  year: 2006
  ident: 10.1016/j.transproceed.2008.03.016_bib9
  article-title: Allocation of nonstandard livers to transplant candidates with high MELD scores: should this practice be continued?
  publication-title: Transplant Proc
  doi: 10.1016/j.transproceed.2006.10.034
– volume: 6
  start-page: 816
  year: 2007
  ident: 10.1016/j.transproceed.2008.03.016_bib8
  article-title: A novel prognostic model based on serum levels of total bilirubin and creatinina early after liver transplantation
  publication-title: Liver Int
  doi: 10.1111/j.1478-3231.2007.01494.x
– volume: 6
  start-page: 1572
  year: 2006
  ident: 10.1016/j.transproceed.2008.03.016_bib5
  article-title: Liver transplantation with the MELD system: A prospective study from a single European center
  publication-title: Am J Transplant
  doi: 10.1111/j.1600-6143.2006.01354.x
– volume: 31
  start-page: 864
  year: 2000
  ident: 10.1016/j.transproceed.2008.03.016_bib2
  article-title: A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts
  publication-title: Hepatology
  doi: 10.1053/he.2000.5852
– volume: 6
  start-page: 783
  year: 2006
  ident: 10.1016/j.transproceed.2008.03.016_bib13
  article-title: Characteristics associated with liver graft failure: The concept of a donor risk index
  publication-title: Am J Transplant
  doi: 10.1111/j.1600-6143.2006.01242.x
– volume: 6
  start-page: 1070
  year: 2006
  ident: 10.1016/j.transproceed.2008.03.016_bib1
  article-title: Liver transplantation in the MELD era: a single center experience
  publication-title: Dig Dis Sci
  doi: 10.1007/s10620-006-8011-1
SSID ssj0004243
Score 1.9675978
Snippet Since July 2006, the liver graft allocation has been changed from the waiting time to the Model for End-stage Liver Disease (MELD), prioritizing the sickest...
Abstract Since July 2006, the liver graft allocation has been changed from the waiting time to the Model for End-stage Liver Disease (MELD), prioritizing the...
SourceID proquest
pubmed
pascalfrancis
crossref
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 797
SubjectTerms Adolescent
Adult
Aged
Biological and medical sciences
Female
Fundamental and applied biological sciences. Psychology
Fundamental immunology
Gastroenterology. Liver. Pancreas. Abdomen
Humans
Liver Diseases - classification
Liver Diseases - surgery
Liver Failure - surgery
Liver Transplantation - mortality
Liver Transplantation - physiology
Liver, biliary tract, pancreas, portal circulation, spleen
Liver. Biliary tract. Portal circulation. Exocrine pancreas
Male
Medical sciences
Middle Aged
Other diseases. Semiology
Portasystemic Shunt, Surgical
Portasystemic Shunt, Transjugular Intrahepatic
Predictive Value of Tests
Surgery
Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases
Surgery of the digestive system
Survival Analysis
Time Factors
Tissue, organ and graft immunology
Treatment Outcome
Title Analysis of Liver Transplantation Outcome in Patients With MELD Score ≥30
URI https://www.clinicalkey.com/#!/content/1-s2.0-S0041134508002194
https://www.clinicalkey.es/playcontent/1-s2.0-S0041134508002194
https://dx.doi.org/10.1016/j.transproceed.2008.03.016
https://www.ncbi.nlm.nih.gov/pubmed/18455020
https://www.proquest.com/docview/69179513
Volume 40
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB71ISQkVEELZQssPqCemtaxEycW4rCUVgstpRKt6M3y5iEWtdlVkz3shTs_pH-sv4RxbO9SUaSVuEVJJo_JZPw5-eYbgDeioCzjSRykAyGCKOfmJ6HOA5bIQiQ6Y5Fu1T5PRP88-nQRXyzBvq-FMbRKl_ttTm-ztVuz57y5Nx4OTY1vFIY8ilvMg3PxZVhlXAoM7dXex6P-ybw8knnyXBgYA6892tK8mlZD3A4WjlrJd6lpf37_OPVorGv0XmnbXvwbl7bj0-FjWHPAkvTstT-BpaJah41ehZPqqynZJi3Vs_2Gvg4P3vul7VMrXT3dIWfzSqx6pzWYiVpPN-DIq5eQUUmODZmDWF30S22LlyryZdKgFwsyrMipVWutybdh8518Pjj-QL4avUxy--uG06dwfnhwtt8PXCOGIEN41gToZy0RyeR5bApZ0d-pFKUsES0iAMjzgcjpQNNMGv8jHilllopSl5FOETFmkj-DlWpUFc-BhEWKmESHQiY48cNjSp5mccpkRkvJWNIB6d2uMqdSbpplXCpPR_uh_nxkro0mV7ipA3xmO7ZaHQtZvfVPV_lqVMyfCoeUhayT-6yL2qWCWoWqZoqqv8K1A-9mlncifuEzd--E4uyWGeUIKiPc4bWPTYU5w_wI0lUxmtRK4BwdkTXvwKYN2bm7UlPlzujWf17cC3hoiTWG4vQSVprrSfEK0Vsz6MLy7s-w697R38ewQ8g
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Nb9NAEB2VIgRShaAFGj7aPaCe6na9a6-9qjiU0irQtFQiFb2tNv4QqVonws4hF-78kP4xfgmzu96EiiJF4hYlnsQZz868td-8AXgrCsoynsRBOhAiiHJuHhLqPGCJLESiMxZpq_Z5Krrn0aeL-GIJDnwvjKFVtrnf5XSbrdt3dltv7o6HQ9PjG4Uhj2KLeXAvfg_uR7h8zerc-THneUTMU-fCwBzulUctyauxCuKuVLTESr5DzfDzu6vUyljX6LvSDb34Nyq11enoCTxuYSXZd2f-FJaKahXW9ivcUl9PyRaxRE97B30VHrz3r7bOnHD1dJv0531Y9bY1mElaT9fg2GuXkFFJeobKQZwq-pV2rUsV-Txp0IcFGVbkzGm11uTrsPlGTg57H8gXo5ZJfv284fQZnB8d9g-6QTuGIcgQnDUBellLxDF5Hps2VvR2KkUpS8SKWP7zfCByOtA0Q6goEQ_FpcxSUeoy0inixUzy57BcjapiHUhYpIhIdChkgts-_E7J0yxOmcxoKRlLOiC921XWapSbURlXypPRLtWfl6wdoskVftQBPrMdO6WOhaz2_NVVvhcVs6fCgrKQdXKXdVG3iaBWoaqZouqvYO3Au5nlrXhf-Jc3boXi7C8zyhFSRnjApo9NhRnDPAbSVTGa1ErgDh1xNe_ACxeyc3elpsed0Zf_eXKb8LDbP-mp3sfT41fwyFFsDNnpNSw33yfFG8RxzWDDrtPfdfhEjA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=proceeding&rft.title=Transplantation+proceedings&rft.atitle=Analysis+of+Liver+Transplantation+Outcome+in+Patients+With+MELD+Score+%E2%89%A530&rft.au=FERRAZ-NETO%2C+B.+H&rft.au=ZURSTRASSEN%2C+M.+P.+V.+C&rft.au=HIDALGO%2C+R&rft.au=MEIRA-FILHO%2C+S.+P&rft.date=2008-04-01&rft.pub=Elsevier+Science&rft.issn=0041-1345&rft.volume=40&rft.issue=3&rft.spage=797&rft.epage=799&rft_id=info:doi/10.1016%2Fj.transproceed.2008.03.016&rft.externalDBID=n%2Fa&rft.externalDocID=20384646
thumbnail_m http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F00411345%2FS0041134508X00041%2Fcov150h.gif